State of the Art: Concise Review
PD-L1 Expression in Lung Cancer

https://doi.org/10.1016/j.jtho.2016.04.014Get rights and content
Under an Elsevier user license
open archive

Abstract

Immunotherapies targeted against programmed death ligand 1 (PD-L1) and its receptor (PD-1) have improved survival in a subset of patients with advanced lung cancer. PD-L1 protein expression has emerged as a biomarker that predicts which patients are more likely to respond to immunotherapy. The understanding of PD-L1 as a biomarker is complicated by the history of use of different immunohistochemistry platforms with different PD-L1 antibodies, scoring systems, and positivity cut-offs for immunotherapy clinical trials with different anti-PD-L1 and anti-PD-1 drugs. Herein, we summarize the brief history of PD-L1 as a biomarker and describe the challenges remaining to harmonize PD-L1 detection and interpretation for best patient care.

Keywords

Lung cancer
Biomarker
PD-L1
Immunotherapy

Cited by (0)

Drs. Yu and Boyle contributed equally to this article.

Disclosure: Dr. Boyle an honorarium from Bristol-Meyers Squibb outside the submitted work. Dr. Rimm reports grants from Genoptix and Gilead Sciences during conduct of the study and personal fees from Bristol-Meyer Squibb and AstraZeneca outside the submitted work. The remaining authors declare no conflict of interest.